| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Inno-Gene S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.59 |
| 52 Week High | zł0.75 |
| 52 Week Low | zł0.27 |
| Beta | 1.18 |
| 11 Month Change | -13.95% |
| 3 Month Change | 33.03% |
| 1 Year Change | -14.20% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| WQ3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 2.1% | 1.3% | 1.1% |
| 1Y | -14.2% | 11.7% | 12.5% |
Return vs Industry: WQ3 underperformed the German Life Sciences industry which returned 12% over the past year.
Return vs Market: WQ3 underperformed the German Market which returned 11.8% over the past year.
Price Volatility
| WQ3 volatility | |
|---|---|
| WQ3 Average Weekly Movement | 22.1% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: WQ3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: WQ3's weekly volatility has increased from 13% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 8 | n/a | www.inno-gene.pl |
Inno-Gene S.A. provides genetic diagnostic solutions in Poland. It is involved in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of HPV-dependent solid tumors.
Inno-Gene S.A. Fundamentals Summary
| WQ3 fundamental statistics | |
|---|---|
| Market cap | €28.84m |
| Earnings (TTM) | -€1.44m |
| Revenue (TTM) | €86.57k |
333.1x
P/S Ratio-20.0x
P/E RatioIs WQ3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WQ3 income statement (TTM) | |
|---|---|
| Revenue | zł373.00k |
| Cost of Revenue | zł683.00k |
| Gross Profit | -zł310.00k |
| Other Expenses | zł5.92m |
| Earnings | -zł6.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | -0.19 |
| Gross Margin | -83.11% |
| Net Profit Margin | -1,668.90% |
| Debt/Equity Ratio | 1.1% |
How did WQ3 perform over the long term?
See historical performance and comparison